First-trimester screening for Down syndrome using quadruple maternal biochemical markers
L Caron, A Fillion, Y Giguère, F Audibert… - Clinical Chemistry and …, 2023 - degruyter.com
Clinical Chemistry and Laboratory Medicine (CCLM), 2023•degruyter.com
Abstract Objectives Placental growth factor (PlGF) is used for first-trimester preeclampsia
screening and could be combined with other biochemical markers for Down syndrome
screening. We aim to estimate the predictive value of the combination of pregnancy-
associated plasma protein (PAPP-A), free β-human chorionic gonadotropin (free β-hCG),
placental growth factor (PlGF) and α-fetoprotein (AFP) with and without nuchal translucency.
Methods Singleton pregnancies recruited at 11–14 weeks and followed until delivery. The …
screening and could be combined with other biochemical markers for Down syndrome
screening. We aim to estimate the predictive value of the combination of pregnancy-
associated plasma protein (PAPP-A), free β-human chorionic gonadotropin (free β-hCG),
placental growth factor (PlGF) and α-fetoprotein (AFP) with and without nuchal translucency.
Methods Singleton pregnancies recruited at 11–14 weeks and followed until delivery. The …
Objectives
Placental growth factor (PlGF) is used for first-trimester preeclampsia screening and could be combined with other biochemical markers for Down syndrome screening. We aim to estimate the predictive value of the combination of pregnancy-associated plasma protein (PAPP-A), free β-human chorionic gonadotropin (free β-hCG), placental growth factor (PlGF) and α-fetoprotein (AFP) with and without nuchal translucency.
Methods
Singleton pregnancies recruited at 11–14 weeks and followed until delivery. The four maternal markers were measured using Kryptor (ThermoFisher-BRAHMS) and adjusted for gestational age and maternal characteristics. The risk of Down syndrome was calculated using the Fetal Medicine Foundation algorithm and multivariate linear regression analyses in all cases and in 2,200 controls. Receiver-operator characteristic (ROC) curves were used to calculate the detection and false-positive rates.
Results
Twenty-six (0.2%) cases of Down syndrome were diagnosed among 13,386 participants. The combination of the four biomarkers could have detected 88% (95% CI: 72–97%) of the cases at a false-positive rate of 13% (95% CI: 12–15%). The addition of nuchal translucency would have increased the detection rate to 96% (95% CI: 82–99%) at a false-positive rate of 4% (95% CI: 4–5%) using a 1:300 cut-off and to 100% (95% CI: 89–100%) at a false-positive rate of 6% (95% CI: 5–8%) using a 1:500 cut-off.
Conclusions
First-trimester screening using biochemical markers allows the identification of approximately 88% of Down syndrome cases for a false-positive rate of 13%. The addition of nuchal translucency raises the detection rate above 95% with a false-positive rate below 5%.
De Gruyter以上显示的是最相近的搜索结果。 查看全部搜索结果